New
Mexico Register / Volume XXXVII, Issue 22 / November 17, 2026
This is an amendment to 16.19.11 NMAC, Section 1, 3, 8, and adding new section 9 effective 11/17/2026.
16.19.11.1 ISSUING
AGENCY:[ Regulation and Licensing Department] Board
of Pharmacy [, Albuquerque,
NM, (505) 841-9102.]
[16.19.11.1 NMAC -
Rp 16 NMAC 19.11.1, 12-15-02; A, 11/17/2026]
16.19.11.3 STATUTORY
AUTHORITY: Paragraph (6) of Subsection A of Section 61-11-6 [A(6)] NMSA 1978 authorizes the board of pharmacy to
license nursing home drug facilities and all places where dangerous drugs are
dispensed or administered and to provide for the inspection of their facilities
and activities. Paragraph (9) of Subsection
B of Section 61-11-14 [B(9)] NMSA 1978 directs the board to issue drug custodial licenses for
licensed nursing homes and to adopt regulations that define and limit those
licenses. Section 61-11-31 NMSA 1978 allows custodial care
facilities authorized to provide withdrawal management to acquire
and possess dangerous drugs
and controlled substances in
accordance with board rules.
[16.19.11.3 NMAC -
Rp 16 NMAC 19.11.3, 12-15-02; A, 11/17/2026]
16.19.11.8 MINIMUM
STANDARDS:
A. Minimum
standards for the distribution, storage, handling and record keeping of drugs:
(1) The
pharmaceutical service shall be organized and maintained primarily for the
benefit and safety of the patient.
(2) All
medications administered to patients shall be by direct order of a physician, or
other licensed practitioner, as defined in the Pharmacy Act, Subsection
P of Section 61-11-2 [P]
NMSA 1978.
(3) The
pharmaceutical service shall be under the direction of a registered pharmacist,
who may be on a part-time or consultant basis.
(4) [Policies relating
to the control, distribution and administration of medications shall be
developed by the pharmacist. Preparation of a written procedures manual shall
be the responsibility of the pharmacist.]
The pharmacist is responsible for developing policies for medication
control, distribution and administration and preparing a written procedures
manual.
(5) An
automatic stop-order policy shall be adopted to provide guidance in these
instances where medications ordered are not specifically limited as to time or
number of doses.
(6) Adequate
facilities to be provided for storage of medications. Proper labeling is
required on each patient's medication container.
(7) Complete
records - In addition to those records specifically required by federal and
state laws, records shall be maintained of the receipt, use, or disposition of
medications. The receipt and destruction
journal shall show:
(a) date;
(b) patient's
name;
(c) pharmacy's
name;
(d) name
of drug;
(e) strength
and dosage form;
(f) prescription
number;
(g) quantity;
(h) initials of person accepting
delivery; and
(i) inventory
of drugs to be destroyed.
(8) Appropriate
current drug reference sources shall be provided at the facility,
in printed or electronic form.
(9) [In licensed
nursing homes an emergency drug supply shall be maintained to be used in a medical emergency situation, contents and
quantity to be determined by a physician, nursing director and the pharmacist
of each institution. In licensed
custodial care facilities an emergency drug supply may
be used. This emergency drug supply
shall be accessed only when licensed personnel are on duty. In licensed custodial care facilities without a 24-hour/365 day per year on-site nurse, the emergency
drug tray shall not contain any controlled substances. Licensed
custodial care facilities, with a 24-hour/365 day per year on-site nurse
may use an emergency drug tray containing controlled substances. A list of the contents of the emergency
drug supply shall be attached to the
outside of the tray.] In licensed nursing
homes, an emergency drug supply must be maintained for medical emergencies, with
its contents and quantity determined
by a physician, nursing director, and the pharmacist of each institution. In licensed custodial care facilities, the
emergency drug supply can be used only when licensed personnel are on duty. Facilities without
a 24/7 on-site nurse cannot include controlled substances in the emergency
drug supply, while those with a 24/7 nurse can. A list of the emergency drug supply's contents must be attached
to the tray.
(10) Medication
errors and adverse drug
reactions [should] will be documented and a method of reporting shall be addressed in the
pharmacy procedure manual.
B. Policy and
procedures manual:
(1) The
pharmacist shall be responsible for the preparation of a written procedures
manual, the aim of which shall be:
(a) To
improve communications with the facility;
(b) to
improve patient care;
(c) to
aid in personnel training;
(d) to
increase legal protection;
(e) to
aid in evaluating performance;
(f) to
promote consistency and continuity.
(2) [There shall be a copy of the policy
and procedure manual at each facility location. This copy must be read and initialed by all personnel
responsible for the procurement, administration or control of the patient's
medication.] Each facility
must have a copy of the policy and procedure manual, which must be read and
initialed by all personnel responsible for procuring, administering, or
controlling patient medication. The
manual may be maintained in paper or electronic form.
(3) [The
consultant pharmacist shall make an annual review of the procedures manual.
Findings of which shall be reported to the facility
administration.] The consultant pharmacist must annually
review the procedures manual and report findings to the facility
administration.
(4) Guidelines
for developing a pharmaceutical procedures manual;
(a) Drug
policy: A written policy [concerning]detailing the methods and procedures for [the]pharmaceutical services, [stating the appropriate methods and procedures for] including obtaining, dispensing and administering drugs and
biologicals.
(b) Prescription
drug orders: The designated agent of the licensed facility may transcribe prescription drug orders from a licensed
practitioner and transmit those orders via telephone or facsimile to the
pharmacy.
(c) Licensed
practitioners will identify the designated agents of a facility by written
authorization according to the facility's policy and procedures manual.
(d) The
facility shall have a medication administration record (MAR) documenting
medications administered to residents, including over-the-counter
medications. This documentation shall
include:
(i) Name
of resident;
(ii) date
given;
(iii) drug
product name;
(iv) dosage
and form;
(v) strength
of drug;
(vi) route
of administration;
(vii) how
often medication is to be taken;
(viii) time
taken and staff initials;
(ix) dates
when the medication is discontinued or changed;
(x) the
name and initials of all staff administering medications.
(e) Any
medications removed from the pharmacy container or blister pack must be given
immediately and documented by the person assisting.
(f) All
PRN medications shall have complete detailed instructions regarding the administering of
the medication. This shall include:
(i) Symptoms
that indicate the use of the medication;
(ii) exact
dosage to be used;
(iii) the
exact amount to be used in a 24 hour period.
(g) Describe
medication storage, procedures, and function at the nursing stations.
(h) Describe
the medication administration system used with means of verifying accuracy of
delivered dosage. Describe the procedure for recording missed or refused doses
and the procedure followed for missed or refused doses.
(i) State
that medications prescribed for one patient shall not be administered to any
other patient.
(j) Describe
policy concerning self-administration of medications by patients. A physician's order shall be required before
any resident is allowed to self-administer medications.
(k) State
procedures for documenting medication errors and adverse drug reactions:
(i) Should
a staff member of the facility notice an error, possible overdose, or any
discrepancy in any of the prescriptions filled by the pharmacy, they will
immediately contact the pharmacy. If
necessary, the pharmacy will contact the physician.
(ii) In
the event of an adverse drug reaction the facility will immediately contact the
physician.
(l) List
labeling and storage requirements of medications in conformity with the
official compendium (USP/NF).
(5) Other
information:
(a) Emergency
drug tray - use, inventory control, replacement of drugs, security when
licensed staff is not on duty.
(b) Location
of emergency drug tray.
(c) 24-hour
emergency pharmaceutical services.
(d) Part-time
or consultant pharmacist hours on premises.
(e) In-service
training.
(f) Drug
information service.
(g) Automatic
stop orders.
(h) Controlled
substances - inventory, security and control.
(i) Renewal
of physician's orders.
(j) A
policy concerning "PASS" medications.
(k) Discontinued
medication.
(l) Records
and standards of storage of over-the-counter drugs.
(m) Drug
receipt and disposition records.
(6) Drug
distribution:
(a) All
dangerous drugs shall be obtained from a properly licensed facility. Stock dangerous
drugs acquired, maintained and administered by or at the nursing home shall be
listed in the nursing home policy and procedure manual. The stock dangerous drugs shall be used when
a licensed nurse (LPN or RN) is on duty.
The following is the approved list of stock dangerous drugs:
(i) Sterile
normal saline and water - injectable;
(ii) sterile
normal saline and water - irrigation;
(iii) tuberculin
testing solution;
(iv) vaccines
[as recommended by the centers
for disease control
(CDC) and prevention’s
advisory committee on immunization practices and] appropriate for the facility population served;
(v) any
additional nursing home stock dangerous drugs must be defined and listed in the
policy and procedure manual and must be approved by the board of pharmacy or
board’s agent prior to obtaining or using.
(b) No
drugs will be compounded by other than a pharmacist unless done in accordance
with that exemption in the State Pharmacy Act - Section 61-11-22 NMSA 1978.
(c) The
pharmacist shall be responsible for the proper removal and destruction of
unused, discontinued, outdated or recalled drugs. The pharmacist shall be responsible for
proper transfer and documentation of eligible drugs donated in accordance with
16.19.34 NMAC.
(d) The
pharmacist shall require the person receiving a patient's drugs from the
pharmacist or his agent to sign a drug receipt record listing those
prescriptions received from the pharmacy.
(e) The
pharmacist shall provide the staff with a receipt listing those prescriptions
removed from the facility.
(f) Medications
will be released to patients on discharge from the facility only upon the
authorization of the physician.
(7) Drug
control:
(a) All
state and federal laws relating to storage, administration and disposal of
controlled substances and dangerous drugs shall be complied with.
(b) Separate
sheets shall be maintained for controlled substances records indicating the following
information for each type and strength of controlled substances: date, time administered, name of patient,
dose, physician’s name, signature of person administering dose, and balance of
controlled substance in the container.
(c) All
drugs shall be stored in locked cabinets, locked drug rooms, or state of the
art locked medication carts.
(d) Medication
requiring refrigeration shall be kept in a secure locked area of the
refrigerator or in the locked drug room.
(e) All
refrigerated medications will be kept in separate refrigerator or compartment
from food items.
(f) Medications
for each patient shall be kept and stored in their originally received
containers, and stored in separate compartments. Transfer between containers is forbidden,
waiver shall be allowed for oversize containers and controlled substances at
the discretion of the drug inspector.
(g) Prescription
medications for external use shall be kept in a locked cabinet separate from
other medications.
(h) No
drug samples shall be stocked in the licensed facility.
(i) All
drugs shall be properly labeled with the following information:
(i) Patient's
full name;
(ii) physician's
name;
(iii) name,
address and phone number of pharmacy;
(iv) prescription
number;
(v) name
of the drug and quantity;
(vi) strength
of drug and quantity;
(vii) directions
for use, route of administration;
(viii) date
of prescription (date of refill in case of a prescription renewal);
(ix) expiration
date where applicable: The dispenser
shall place on the label a suitable beyond-use date to limit the patient's use
of the medication. Such beyond-use date
shall be not later than (a) the expiration date on the manufacturer's
container, or (b) one year from the date the drug is dispensed, whichever is
earlier;
(x) auxiliary
labels where applicable;
(xi) the
manufacturer's name;
(xii) state
of the art drug delivery systems using unit of use packaging require items i and
ii above, provided that any additional information is readily available at the
nursing station.
[ (j) Customized Patient Medication
Packages: In lieu of dispensing one, two, or more prescribed drug products in
separate containers or standard vial containers, a pharmacist may, with the
consent of the patient, the patient's caregiver, the prescriber, or the
institution caring for the patient, provide a customized patient medication package.
The pharmacist preparing a patient medication package must abide by the
guidelines as set forth in the current edition of the U. S. Pharmacopoeia for
labeling, packaging and record keeping.
(k) Repackaging of Patient Medication
Packages: In the event a drug is added to or discontinued from a patient's drug
regimen, when a container within the patient medication package has more than
one drug within it, the pharmacist may repackage the patient's patient medication
package and either add to or remove from the patient medication packaged as
ordered by the physician. The same drugs returned by the patient for
repackaging must be reused by the pharmacist in the design of the new patient
medication package for the new regimen, and any drug removed must either be
destroyed, returned to the DEA or returned to the patient properly labeled.
Under no circumstances may a drug within a container of a patient medication
package which contains more than one drug be returned to the pharmacy stock.
(l) Return of Patient Medication Package
Drugs: Patient medication packages with more than one drug within a container
may not under any circumstances be returned to a pharmacy stock.
(m) Patient Medication Packages with only
one drug within a container:
(i) Non-Institutional: A patient
medication package stored in a non-institutional setting where there is no assurance
of storage standards may not be returned to pharmacy stock;
(ii) Institutional: A patient medication
package stored in an institutional setting where the storage and handling of
the drugs are assured and are consistent with the compendia standards may be
returned to the pharmacy stock provided the following guidelines are followed:
(1) the drug is to be kept within the patient medication package and is to
remain sealed and labeled until dispensed; (2) the expiration date of drug shall
become 50% of the time left of the expiration for the drug; (3) no Schedule II
drugs may be returned to inventory; and (4) proper record keeping for the
addition of other scheduled drugs into inventory must be done.]
(8) Drug
information:
(a) The
pharmacist shall be accessible for providing drug information.
(b) A
current drug reference [books] shall be located in each nursing station, and may
be in paper or electronic form.
(c) Each
nursing station shall have poison control information and phone number and a
conversion chart for pharmaceutical weights and measures, and as a part of the
drug procedures manual.
(9) Emergency
drug supply
(a) There
shall be an accountability record indicating the following:
(i) Name
of drug, strength, and amount of medication used;
(ii) date
used;
(iii) time;
(iv) patient's
name;
(v) physician's
name;
(vi) nurse
administering drug;
(vii) nature
of emergency.
(b) Pharmacist
shall make notation of date and time medication replacement is made on the line
following that line containing withdrawal information and sign his name, unless
the pharmacy chooses to change out the complete emergency box each time it is
used. The pharmacy shall keep a record
of each time the box is changed and a list of all drugs that were replaced in
the box.
(10) Destruction
of dispensed drugs for patients in health care facilities or institutions:
(a) The
drugs are inventoried and such inventory is verified by the consultant
pharmacist. The following information
shall be included on this inventory:
(i) name
and address of the facility or institution;
(ii) name
and pharmacist license number of the consultant pharmacist;
(iii) date
of drug destruction;
(iv) date
the prescription was dispensed;
(v) unique
identification number assigned to the prescription by the pharmacy;
(vi) name
of dispensing pharmacy;
(vii) name,
strength, and quantity of drug;
(viii) signature
of consultant pharmacist destroying drugs;
(ix) signature
of witness(es); and
(x) method
of destruction.
(b) The
drugs are destroyed in a manner to render the drugs unfit for human consumption
and disposed of in compliance with all applicable state and federal
requirements.
(c) The
actual destruction of the drug is witnessed by the consultant pharmacist and
one of the following:
(i) An
agent of the New Mexico board of pharmacy;
(ii) facility
administrator;
(iii) the
director of nursing.
(11) A
consultant pharmacist may utilize a waste disposal service or reverse
distributor to destroy dangerous drugs and controlled substances in health care
facilities, boarding homes or institutions provided the following conditions
are met:
(a) The
inventory of drugs is verified by the consultant pharmacist. The following information must be included on
this inventory:
(i) Name
and address of the facility or institution;
(ii) name
and pharmacist license number of the consultant pharmacist;
(iii) date
of packaging and sealing of the container;
(iv) date
the prescription was dispensed;
(v) unique
identification number assigned to the prescription by the pharmacy;
(vi) name
of dispensing pharmacy;
(vii) name,
strength and quantity of drug;
(viii) signature
of consultant pharmacist packaging and sealing container; and
(ix) signature
of the witness.
(b) The
consultant pharmacist seals the container or drugs in the presence of the
facility administrator, the director of nurses or an agent of the board of
pharmacy.
(c) The
sealed container is maintained in a secure area at the facility or pharmacy
until transferred to the waste disposal service or the reverse distributor by
the consultant pharmacist, facility administrator, director of nursing or agent
of the board of pharmacy.
(d) A
record of the transfer to the waste disposal service or reverse distributor is
maintained and attached to the inventory of drugs. Such records shall contain the following
information:
(i) Date
of the transfer;
(ii) signature
of the person who transferred the drugs to the waste disposal service or
reverse distributor;
(iii) name
and address of the waste disposal service or reverse distributor;
(iv) signature
of the employee of the waste disposal service or the reverse distributor who receives
the container; and
(v) the
waste disposal service or reverse distributor shall provide the facility with
proof of destruction of the sealed container.
(12) Record
retention: All records required above
shall be maintained by the consultant pharmacist and the health care facility
or institution for three years from the date of destruction.
[16.19.11.8 NMAC -
Rp 16.19.11.8, 12/15/2002; A, 10/24/2014; A, 12/13/2015; A, 11/17/2026]
16.19.11.9 CUSTODIAL CARE FACILITY – WITHDRAWAL MANAGEMENT:
A. A licensed custodial care facility
that is authorized to provide medically monitored withdrawal management that is
under the supervision of a consultant pharmacist and has nursing staff on-site
24 hours per day, 365 days per year, may acquire, stock, maintain and have in
the facility's possession dangerous drugs, including controlled substances only
in Schedules III–V as limited in Paragraph (4) of Subsection D of this section,
for administration for withdrawal management purposes, in accordance with board
rules.
B. Definitions as used in this section:
(1) “administer” means the direct
application of a drug to the body of a patient or research subject by
injection, inhalation, ingestion or any other means as a result of an order of
a licensed practitioner.
(2) “authorized personnel” means licensed
healthcare professionals acting within their scope of practice who:
(a) are specifically authorized by facility
policy to access, handle, or administer dangerous drugs or controlled
substances;
(b) are listed on the current
authorized access roster with date granted and terminated; and
(c) have documented completion of
initial training required by Paragraph (2) of Subsection H of this section
prior to being granted access or administration authority.
(3) “downtime” means any period
during which the primary electronic access or record system is unavailable.
(4) “emergency override” means
any access to controlled substances outside normal access controls as permitted
by facility policy during downtime or urgent care.
(5) “facility stock” means
dangerous drugs, including controlled substances, maintained by the facility
under its board and DEA registrations for administration to facility patients
and not dispensed to a specific patient.
(6) “MAR reconciliation” means the
documented comparison of MAR entries to the perpetual inventory, wastage, and
access logs to confirm agreement.
(7) “medically monitored withdrawal
management” means withdrawal management services provided under medical
supervision, including the use of dangerous drugs authorized under this
section, consistent with patient assessment, monitoring, documentation, and
staffing requirements in Subsections G and H of this section and other
applicable state and federal regulations.
(8) “perpetual inventory” means
a continuously maintained record that reflects the on-hand quantity after each
receipt, administration, wastage, transfer, or destruction entry, with running
balance.
(9) “significant loss” has the
meaning provided in 16.19.20 NMAC and applicable DEA regulations.
(10) “variance” means any difference
between the physically counted quantity and the documented perpetual inventory
balance; “variance greater than zero” means any non-zero difference, positive
or negative.
(11) “wastage” means the
irreversible disposal of a remaining portion of a dose not administered to a
patient.
C. Licensure: Before acquiring or possessing stock dangerous
drugs, including controlled substances, the facility must:
(1) be licensed by the board to
operate as a custodial facility providing withdrawal management;
(2) be licensed by the board to
operate as a limited drug clinic as described in Paragraph (3) of Subsection A
of 16.19.10.11 NMAC, or successor provision; and
(3) hold current board and DEA controlled
substance registrations issued for, and listing, the facility’s physical street
address.
D. Minimum Standards:
(1) Custodial care withdrawal
management facilities shall comply with 16.19.11.8 NMAC of this part and
16.19.10 NMAC, as applicable. For facility stock this section governs and
controls over conflicting provisions in 16.19.11.8 NMAC of this part and
16.19.10 NMAC. The requirements in Paragraphs (10) through (12) of Subsection B
of 16.19.11.8 NMAC of this part apply only to dispensed, patient-specific
drugs; destruction or reverse distribution of facility stock controlled substances
shall comply with 16.19.20.38 NMAC and 21 CFR Part 1317. Nothing in this
section alters labeling and MAR documentation requirements applicable to
patient-specific medications under 16.19.11.8 NMAC of this part.
(2) Consultant pharmacist: All
custodial care withdrawal management facilities shall engage the services of a
pharmacist whose duties and responsibilities are described in 16.19.4.11 NMAC,
pertaining to custodial facilities and clinics. The pharmacist shall review one
hundred percent of active patient charts at least quarterly and shall perform a
drug regimen review for each newly admitted patient within 72 hours of
admission or by the next business day if the 72-hour period includes a state or
federal holiday. The pharmacist shall reconcile all controlled substances and
gabapentin (and any additional dangerous drugs designated by facility policy)
at each quarterly visit, review all required perpetual inventories, reconciliation
records, emergency par levels, and analyze variances and wastage for issues or
patterns. As part of reconciliation, the pharmacist shall obtain, from the
contracted pharmacy, all records of facility stock procured during the
quarterly reconciliation period. Discrepancies identified during quarterly
reconciliation must be documented and addressed under Subsection I of this
section. The pharmacist quarterly report shall document completion of required
activities and a quarterly reconciliation report summarizing counts, variances,
wastage analysis, access log review, procurement vs. usage reconciliation,
discrepancies identified, investigations initiated under Subsection I of this
section, and corrective actions.
(3) Medical director: The facility
shall be under the supervision of a medical director responsible for
prescribing for facility patients. Controlled substances may be prescribed only
by an appropriately registered individual practitioner acting in the usual
course of professional practice for a legitimate medical purpose.
(4) Stock eligibility: Facility stock
controlled substances are limited to Schedules III–V and may be administered
for clinically appropriate withdrawal management or directly related supportive
care indications documented in the medical record. If the controlled substance
is an opioid, it must be FDA-approved for maintenance or detoxification and used
consistent with state and federal law. Schedule II controlled substances may
not be maintained, stocked, or administered as facility stock under this
Section.
(5) No separate emergency drug
supply. A facility operating under this
Section shall not acquire, stock, or maintain a separate emergency drug supply,
emergency drug tray, or emergency kit of facility-stock controlled substances
under Paragraph (9) of Subsection B of 16.19.11.8 NMAC of this part. Surge and emergency
access needs shall be met through facility stock maintained within the
perpetual inventory, including the emergency par level authorized under
Subsection F of this section. Nothing in this paragraph limits a
patient-specific medication order or the administration of facility stock for
withdrawal management or directly related supportive care under Paragraph (4)
of this subsection.
E. Patient-specific
medications: Self-administration requires a prescriber order and must conform to
facility policy and applicable law. The facility shall not take possession of
patient-specific controlled substances unless possession and custody are
authorized by applicable state and federal law. When authorized,
patient-specific dangerous drugs and controlled substances shall be:
(1) logged upon receipt with patient name, drug,
strength, quantity, and source;
(2) stored separately from facility
stock in a securely locked manner preventing contamination and diversion;
(3) administered only pursuant to a
valid order and documented on the MAR;
(4) tracked on separate controlled
substance count sheets or electronic equivalent capturing all elements in
Subparagraph (b) of Paragraph (7) of Subsection B of 16.19.11.8 NMAC of this
part or successor provision. Patient-specific controlled substances in facility
custody shall be included in the shift-change joint physical count and
reconciliation required by Paragraph (5) of Subsection G of this section; and
(5) returned, transferred, or
destroyed in accordance with applicable law when therapy is discontinued or
upon discharge.
F. Contracted pharmacy; unit-dose stock: Facilities may
obtain manufacturer or pharmacy-prepared unit dose stock dangerous drugs and
controlled substances from a contracted pharmacy. Solid oral dosage forms must
be in unit-dose packaging; bulk bottles are not allowed. Quantities procured
and maintained shall not exceed the documented average 30-day utilization by drug
and strength, calculated using at least the prior three months (or all
available months if fewer than three) of facility administration data, plus an
emergency par level. Initial quantities obtained upon facility licensure shall
be documented in a written utilization projection prepared by the facility and
approved by the consultant pharmacist, including anticipated census, acuity,
and formulary
rationale. For new formulary items, the facility shall prepare
a written utilization projection approved by the consultant pharmacist. The
policy and procedure manual shall designate a primary and one back-up
contracted pharmacy. Changes in the primary or back-up contracted pharmacy
shall be reported to the board within 15 days in the manner prescribed by the
board. For purposes of this Section, ‘emergency par level’ means an additional
on-hand quantity not to exceed twenty-five percent of the calculated 30-day average.
The consultant pharmacist may approve higher temporary par levels with written
justification based on census volatility, acuity, or formulary changes; such
approvals shall be documented and reviewed at least quarterly. Emergency par
levels must be documented and approved by the pharmacist at least quarterly.
G. Storage; access; records; reconciliation; retention;
security:
(1) Facilities must comply with all
applicable state and federal regulations regarding the handling and storage of dangerous
drugs including controlled substances. Access to the drug storage area will be
limited to authorized personnel. Patients may not enter the drug storage area
under any circumstance. The Inspector will evaluate for adequate security of
facility and controls as part of prelicensing.
(2) Controlled substances shall be
stored in a securely locked, substantially constructed cabinet or safe meeting
applicable state and federal physical security requirements, with access limited
to authorized personnel. Access shall be controlled by documented key or code
management with a current authorized access list; if physical keys are used,
they shall be maintained under the control of authorized personnel and never
left unattended. Any spare key shall be maintained sealed with a numbered,
tamper-evident seal with seal number logged and verified at each shift change
when the duty key is passed to the incoming authorized personnel. Upon
discovery of an unexplained broken or mismatched spare key seal, the outgoing
and incoming authorized personnel shall immediately secure the spare key with a
new numbered, tamper-evident seal, document the new seal number before
completing handoff, initiate an internal discrepancy review under Subsection I
of this section, and notify the consultant pharmacist and medical director
within 24 hours. Electronic access systems shall maintain an auditable access
log. Facilities utilizing electronic access systems shall implement a secondary
contingency access protocol that maintains auditable controls during downtime.
Emergency override access shall require dual authorization whenever two
authorized personnel are on duty, regardless of system functionality; where
only one authorized person is on duty, real-time supervisory notification and
post-event supervisory attestation are required. Downtime and override access events
shall be contemporaneously logged, including the reason for the override and
the identity of the authorizing supervisory personnel, and retained with the
perpetual inventory records, with corresponding perpetual inventory entries
cross-referencing the downtime or override access. The authorized access list
shall be reviewed at least quarterly and updated immediately upon any personnel
change affecting access. Temporary or agency staff may be authorized only if
listed on the current access list. Temporary or agency staff shall not be
granted access until license verification is completed and initial training
under Paragraph (2) of Subsection H of this section is documented. Non-licensed
personnel shall not be granted access.
(3) Records: Facilities shall maintain
accurate, contemporaneous records of all dangerous drugs and controlled
substances received, administered, transferred, wasted, or destroyed,
consistent with the Drug, Device and Cosmetic Act, the Controlled Substances
Act, 16.19.20 NMAC, and federal regulations. All transactions affecting on-hand
quantities shall be reflected in the perpetual inventory. Late entries or
corrections shall be dated, timed, and signed or electronically authenticated
by the individual making the entry, shall not obliterate the original entry,
and shall state the reason for the correction. Backdating, overwriting, or
alteration of original balances is prohibited; corrections shall be made as
additive, attributed entries with cross-reference to the original entry.
Electronic records shall maintain unique user identification and an immutable
audit log of entries, corrections, and access. All records required by this
section, including access logs, downtime/override logs, perpetual inventory,
MAR reconciliation logs, wastage documentation, and quarterly reconciliation
reports, shall be maintained in a centralized, indexed record system
(electronic or paper) and be readily available for inspection.
(4) Administration records: The
perpetual inventory record of facility stock administered shall be updated at
the time of administration and include the name of patient; date and time
administered; name of drug; strength of drug; amount administered; balance
remaining; name of prescribing practitioner and name of person administering
the drug. For controlled substances, any partial dose wastage must be co‑witnessed
and co‑signed by a second authorized personnel as defined in Paragraph
(2) of Subsection G of this section, present at the time of wastage, who
positively identifies the drug to be destroyed, and the running balance updated
immediately. If only one authorized person is on duty, secure temporary
sequestration must use a single-use, tamper-evident container placed within the
controlled substance cabinet or safe; the seal number shall be documented on
the perpetual inventory and MAR, and the co-witness wastage shall occur at the
next shift change. Facilities may adopt the co-witness standard for gabapentin
by policy. Administration shall also be documented on the MAR consistent with
Paragraph (4) of Subsection B of 16.19.11.8 NMAC of this part. Each shift shall
verify completion of MAR entries for doses administered during that shift; any
omissions shall be corrected with attributed late entries consistent with
Paragraph (3) of Subsection G of this section. Facilities shall reconcile, at
least weekly, all controlled substances and gabapentin by comparing MAR
entries, perpetual inventory entries, documented wastage, and downtime/override
logs; discrepancies shall be treated as internal discrepancies under Subsection
I of this section. Reconciliation shall be documented.
(5) Inventory and reconciliation: A
perpetual inventory system shall be maintained for facility stock controlled
substances and gabapentin (and any additional dangerous drugs designated by facility
policy) and updated at the time of receipt, administration, wastage or
destruction. At each shift change, outgoing and incoming licensed personnel
shall jointly perform a physical count of all controlled substances, including
any patient-specific controlled substances, and reconcile to the perpetual
inventory or controlled substance count sheet at handoff. The facility may
adopt the same shift change standard for gabapentin; regardless, weekly reconciliation
under Paragraph (4) of Subsection G of this section remains required. Any
variance greater than zero identified at shift handoff shall be jointly
reviewed contemporaneously; if not resolved by corrective documentation before
the end of the handoff process, it shall be treated as an internal discrepancy
under Subsection I of this section. External reporting to the board and DEA
shall follow the ‘theft or significant loss’ standards in Paragraph (1) of
Subsection I of this section.
(6) Diversion controls: The facility
shall provide effective controls and procedures to guard against theft and
diversion of dangerous drugs and controlled substances.
(7) Restricted area room requirements.
Facility stock, including controlled substances, shall be stored in a
restricted area that is a dedicated, enclosed room of adequate size to permit
orderly storage, accurate counting, and reconciliation of all drugs maintained.
The restricted area shall be: (a) of substantial construction, with walls, ceiling,
floor, and door sufficient to resist unauthorized entry; (b) secured by
controlled-access locking consistent with Paragraph (2) of Subsection G of this
section, with access limited to authorized personnel and with patients
prohibited from entry under any circumstance, consistent with Paragraph (1) of
Subsection G of this section; (c) equipped with climate control adequate to
maintain drugs within the storage conditions required by Paragraph (8) of this subsection;
and (d) evaluated by the inspector for adequate size, construction, and
security as part of prelicensing and inspection under Paragraph (1) of
Subsection G of this section.
(8) Temperature monitoring. The
facility shall monitor and maintain the temperature (and, where applicable,
humidity) of each drug storage area, including any refrigerated storage, within
the manufacturer’s recommended range and applicable United States Pharmacopeia standards.
Monitoring shall be documented on a contemporaneous log, excursions shall be
recorded and acted upon under facility policy, and monitoring records shall be
maintained and available for inspection consistent with Paragraph (3) of
Subsection G of this section.
(9) Video surveillance. The facility
shall maintain a functioning video camera providing continuous coverage of the
restricted area. Recorded footage shall not be altered, edited, or deleted by facility
staff, shall be secured against tampering, and shall be retained for at least
ninety (90) days and made available to the board or its agent upon request.
H. Administration authority; training:
(1) Only authorized personnel may
administer dangerous drugs, including controlled substances.
(2) All personnel involved in
handling, storage, reconciliation, administration, or documentation of
controlled substances must complete initial and at least annual refresher training
(in person or virtual) on applicable state and federal regulations and facility
policies, including designated agent identification and order transmission
consistent with Subparagraphs (b) and (c) of Paragraph (4) of Subsection B of
16.19.11.8 NMAC of this part, storage and access controls (Paragraph (2) of
Subsection G of this section), recordkeeping and perpetual inventory (Paragraph
(3) of Subsection G of this section), wastage (Paragraph (4) of Subsection G of
this section), reconciliation (Paragraph (5) of Subsection G of this section),
and requirements under Subsection I of this section. Initial training shall
occur prior to independent access or administration authority. Training documentation
shall be maintained in personnel files or a centralized record and be readily
available for inspection.
I. Reporting discrepancies, theft, or loss; written
policy:
(1) Any theft or significant loss of controlled
substances must be reported to the board in accordance with 16.19.20 NMAC and
to DEA in accordance with federal requirements, within required time frames.
The facility shall contemporaneously document the assessment of significance,
including quantity lost, specific controlled substance involved, pattern or
aggregate loss over time, and potential diversion risk, and whether the loss
can be associated with known, documented cause, and reporting determinations.
Internal investigation timelines do not delay external reporting.
(2) For this section,
‘discrepancy’ includes unresolved count variances, suspected diversion,
or unexplained losses identified during reconciliation. Facilities must
maintain a written policy establishing:
(i) internal reporting shall occur no
later than the end of the shift in which a discrepancy is discovered, notice
shall also be provided to the consultant pharmacist and medical director in
writing within 24 hours;
(ii) an investigation shall be
initiated within 24 hours and, absent extenuating circumstances documented in
the file, completed within five business days, with interim controls
implemented as indicated (e.g. enhanced counts, restricted access); and
(iii) corrective actions and
reconciliation updates shall be documented within 24 hours of final
determination of root cause, and the perpetual inventory updated to reflect
final resolution.
(3) All investigation and corrective action
records shall be retained for three years from the date of final determination
and be readily available for inspection.
J. Procurement, ordering authority, and transport of
facility stock:
(1) Designated ordering authority. The
facility’s policy and procedure manual shall name one designated licensed
person, approved by the consultant pharmacist, as the sole individual
authorized to order facility-stock dangerous drugs, including controlled substances,
from the contracted pharmacy. The facility shall name a designated back-up only
as provided in the policy and procedure manual and approved by the consultant
pharmacist.
(2) Notice to pharmacies. The
consultant pharmacist shall notify the primary contracted pharmacy and the one
back-up contracted pharmacy designated under Subsection F of this section of
the identity of the authorized designated licensed person, and shall notify
both pharmacies of any change without delay.
(3) Authorized pickup roster. The
facility shall perpetually maintain a current list of its licensed staff and
shall provide that list, and any update to it, to each contracted pharmacy.
Only an individual appearing on the current list, and only while on duty, may
pick up medication from a contracted pharmacy.
(4) Direct transit. Transport of
medication shall proceed directly from the facility to the contracted pharmacy
and directly back to the facility, with no intervening stops.
(5) Transit log. The facility shall
maintain a log of all medication transits sufficient to permit reconciliation,
recording at minimum the time of departure, the time of return, the identity of
the individual transporting the medication, and receipt information adequate to
reconcile the drugs received against the perpetual inventory under Paragraph
(5) of Subsection G of this section.
K. Temporary closure: If a facility temporarily closes, all
dangerous drugs including controlled substances shall be removed from the
facility no later than the time of closure and properly dispositioned by the
consultant pharmacist in accordance with applicable state and federal law.
Disposition shall be documented, and the perpetual inventory reconciled to zero
on-hand for facility stock as of closure.
L. Emergency relocation: A facility
may not resume acquiring, stocking, or maintaining facility-stock dangerous drugs
or controlled substances at a relocated site until the facility has notified
the board of the relocation, the relocated site has been inspected, and the
board has approved drug storage operations at the new location. Board and DEA
controlled-substance registrations must list the facility’s current physical
street address consistent with Paragraph (3) of Subsection C of this section
before facility stock is maintained at the new site.
[16.19.11.9 NMAC –
N, 11/17/2026]